Study Compares Low-Dose BMP to Autograft for Spinal Fusion

Scaffolds loaded with low-dose recombinant bone morphogenic protein-2 is comparable to autograft bone as a bone graft substitute for anterior lumbar interbody fusion in a large animal model, according to a study published in Spine.

Advertisement

Researchers performed anterior lumbar interbody fusion in 11 Yorkshire pigs with either medical grade poly-20 percent tricalcium phosphate, autologous bone grafts, mPCL/TCP  and bone marrow-derived multipotent stromal cells or a combination of mPCL/TCP and 0.6 mg of rhBMP-2.

The group with BMSCs lagged behind autograft bone and rhBMP-2, although there was evidence of bone growth that could constitute additional research. There was no implant rejection, chronic inflammation or other complications.

The authors suggested mPCL/TCP scaffolds loaded with rhBMP-2 or BMSCs could be a good alternative to conventional cages and autograft bone.

Related Articles on BMP:

Study: BMP Use Increases Complication Risk Only in Anterior Cervical Fusion

Study: 85% of BMP Procedures Between 2002 and 2007 Used for Off-Label Applications

NASS: BMP Use in Spinal Fusions May Cause Male Infertility

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spine

Advertisement

Comments are closed.